



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 07 2002

TECH CENTER 1600/2900

Applicants: Gosselin, *et al.*

Serial No.: 10/022,276

Filed: 14-Dec-2001

Title: B-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B Virus

Assistant Commissioner for Patents
Washington, DC 20231

February 25, 2002


Transmittal of Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,


Josephine Young
Reg. No. 48,308

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-2882 (Telephone)
404-572-5145 (Facsimile)



INFORMATION DISCLOSURE STATEMENT
Docket No. 06171.105005
10/022,276


RECEIVED

MAR 07 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Josephine Young

Date: February 25, 2002